Veracyte, Inc. (VCYT)
| Market Cap | 3.23B +28.7% |
| Revenue (ttm) | 541.74M +16.9% |
| Net Income | 88.01M +166.3% |
| EPS | 1.08 +160.6% |
| Shares Out | 79.79M |
| PE Ratio | 37.44 |
| Forward PE | 23.23 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,159,335 |
| Open | 40.76 |
| Previous Close | 40.76 |
| Day's Range | 38.71 - 41.03 |
| 52-Week Range | 22.61 - 50.71 |
| Beta | 1.88 |
| Analysts | Strong Buy |
| Price Target | 44.86 (+10.99%) |
| Earnings Date | May 5, 2026 |
About VCYT
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its n... [Read more]
Financial Performance
In 2025, Veracyte's revenue was $517.15 million, an increase of 16.01% compared to the previous year's $445.76 million. Earnings were $66.35 million, an increase of 174.89%.
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for VCYT stock is "Strong Buy." The 12-month stock price target is $44.86, which is an increase of 10.99% from the latest price.
News
Veracyte price target raised to $42 from $40 at Canaccord
Canaccord analyst Kyle Mikson raised the firm’s price target on Veracyte (VCYT) to $42 from $40 and keeps a Hold rating on the shares. The firm said the target increase
Veracyte price target raised to $52 from $48 at UBS
UBS raised the firm’s price target on Veracyte (VCYT) to $52 from $48 and keeps a Buy rating on the shares.
Veracyte Earnings Call Transcript: Q1 2026
Q1 2026 saw 21% revenue growth and strong profitability, driven by Decipher and Afirma test expansion. Guidance for 2026 was raised, with new product launches (Prosigna LDT, TrueMRD) expected to fuel future growth. Robust clinical evidence and operational improvements underpin long-term momentum.
Veracyte Announces First Quarter 2026 Financial Results
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced financial results for the first quarter ended March 31, 2026. “We had...
Veracyte announces new data at AUA 2026 on Decipher portfolio
Veracyte (VCYT) announced that more than 15 studies focused on the Decipher portfolio will be presented at the 2026 American Urological Association, AUA, Annual Meeting, taking place May 15-18 in
Veracyte Announces New Data at AUA 2026 Highlighting the Power of the Decipher Portfolio to Advance Personalized Care in Urologic Cancers
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT #AUA26--Veracyte Announces New Data at AUA 2026 Highlighting the Power of the Decipher Portfolio to Advance Personalized Care in Urologic Cancers...
Veracyte price target lowered to $40 from $43 at Canaccord
Canaccord lowered the firm’s price target on Veracyte (VCYT) to $40 from $43 and keeps a Hold rating on the shares. The firm updated its model ahaead of Q1 results
Veracyte to Release First Quarter 2026 Financial Results on May 5, 2026
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that it will release financial results for the first quarter 2026 aft...
Veracyte initiated with a Buy at Jefferies
Jefferies initiated coverage of Veracyte (VCYT) with a Buy rating and $45 price target The firm sees “secular tailwinds” in the oncology diagnostics space from improving therapies and declining sequen...
Veracyte price target lowered to $45 from $50 at Guggenheim
Guggenheim lowered the firm’s price target on Veracyte (VCYT) to $45 from $50 and keeps a Buy rating on the shares. The firm adjusted models and forecasts for select companies
Veracyte names Kevin Haas as Chief Development and Technology Officer
Veracyt announced that Kevin Haas, Ph.D., has been appointed Chief Development and Technology Officer, a newly created leadership role designed to advance and scale the company’s global product develo...
Veracyte Names Kevin Haas as Chief Development and Technology Officer
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT #CancerDiagnostics--Veracyte Names Kevin Haas as Chief Development and Technology Officer.
Veracyte Transcript: Leerink Global Healthcare Conference 2026
Management is focused on high-ROI products, maintaining a 25% EBITDA margin, and launching Prosigna and MRD platforms. Decipher and Afirma drive growth through evidence, share gains, and technology upgrades, while AI and data initiatives support future innovation. Prosigna and MRD launches are expected to build momentum beyond 2026.
Veracyte price target lowered to $37 from $48 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Veracyte (VCYT) to $37 from $48 and keeps an Underweight rating on the shares. The firm updated its model following Q4 results.
Veracyte Transcript: 47th Annual Raymond James Institutional Investor Conference
The conference highlighted robust 2025 growth, with $517M revenue and strong adoption of Decipher and Afirma tests. Strategic launches in MRD and breast cancer, digital pathology integration, and international expansion are set to drive double-digit growth and maintain industry-leading margins in 2026.
Veracyte reports Q4 EPS 51c, consensus 41c
Reports Q4 revenue $140.6M, consensus $135.8M. “We delivered an exceptional finish to 2025, with strong double-digit growth across both Decipher and Afirma and more than 45,000 patients served with ou...
Veracyte sees FY26 revenue $570M-$582M, consensus $570.3M
The company is “reiterating 2026 total revenue guidance of 10% to 13% growth, or $570 million to $582 million, driven by testing revenue guidance of 14% to 16% growth, or
Veracyte Earnings Call Transcript: Q4 2025
Q4 and full-year 2025 saw strong revenue and volume growth, with Decipher and Afirma driving results and profitability exceeding targets. 2026 guidance calls for 10–13% revenue growth, continued investment in new product launches, and stable margins, supported by a robust cash position and expanding clinical evidence.
Veracyte Announces Fourth Quarter and Full Year 2025 Financial Results
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced financial results for the fourth quarter and full year ended December...
Veracyte to Highlight Extensive Decipher® Data at 2026 ASCO GU Symposium
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT #ASCOGU--Veracyte to Highlight Extensive Decipher® Data at 2026 ASCO GU Symposium.
Veracyte to Participate in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today it will participate in the following investor conferences. Raymond Ja...
Veracyte to Release Fourth Quarter and Full-Year 2025 Financial Results on February 25, 2026
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that it will release financial results for the fourth quarter and ful...
Veracyte Transcript: 44th Annual J.P. Morgan Healthcare Conference
The conference highlighted robust financial growth, industry-leading profitability, and a strong innovation pipeline, with Decipher and Afirma driving core business and new launches like True MRD and ProSigna set to expand market reach. Continued evidence generation and disciplined capital allocation underpin long-term growth.
Veracyte reports preliminary Q4 revenue $138M-$140M, consensus $131.75M
“I am immensely proud of the impact our tests have had on the more than 800,000 patients we have served since the company’s inception,” said Marc Stapley, Veracyte’s (VCYT) chief
Veracyte sees FY26 revenue $570M-$582M, consensus $565.76M
Veracyte (VCYT) is initiating 2026 total revenue guidance of 10% to 13% growth, or $570 million to $582 million, with testing revenue guidance of 14% to 16% growth, or $559